In fact, faster weight losswhich indicates effective GLP-1/GIP signalingcan trigger more noticeable telogen effluvium
Disclosure The authors declared that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest
Not revolutionary, but certainly not nothing
A., Munzel U., Yakhno N., Raz I., Novosadova M., Maus J., Samigullin, R
In 2021, a new GLP-1 receptor agonist, semaglutide 2.4mg, was approved by the US Food and Drug Administration (FDA) for the management of chronic obesity
"Generic products are an important step in breaking the access barrier, now that the scientific one has been overcome." Indian firms will be a key driving force, with Dr Reddy's Laboratories aiming to launch its version of semaglutide in Canada by May 2026